{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:52:27Z","timestamp":1791334347668,"version":"4.3.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017959","name":"Health Commission of Hebei Province","doi-asserted-by":"publisher","award":["20230296"],"award-info":[{"award-number":["20230296"]}],"id":[{"id":"10.13039\/100017959","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-06261-2","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:07:37Z","timestamp":1783926457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolocumab in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis of efficacy and safety"],"prefix":"10.1186","volume":"26","author":[{"given":"Sha","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuigai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"25","key":"6261_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982\u20133021.","journal-title":"J Am Coll Cardiol"},{"issue":"32","key":"6261_CR2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"1","key":"6261_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","volume":"14","author":"UK Sampson","year":"2012","unstructured":"Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14(1):1\u201310.","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"6261_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40256-023-00594-5","volume":"23","author":"DT Michaeli","year":"2023","unstructured":"Michaeli DT, Michaeli JC, Albers S, Boch T, Michaeli T. Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention. Am J Cardiovasc Drugs. 2023;23(5):477\u201395.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"6261_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/phar.4635","volume":"45","author":"CL Garwood","year":"2025","unstructured":"Garwood CL, Cabral KP, Brown R, Dixon DL. Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review. Pharmacotherapy. 2025;45(1):54\u201365.","journal-title":"Pharmacotherapy"},{"issue":"18","key":"6261_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"12","key":"6261_CR7","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6261_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamacardio.2020.3151","volume":"6","author":"P Deedwania","year":"2021","unstructured":"Deedwania P, Murphy SA, Scheen A, et al. Efficacy and Safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER randomized clinical trial. JAMA Cardiol. 2021;6(2):139\u201347.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"6261_CR9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamacardio.2020.0882","volume":"5","author":"B Gencer","year":"2020","unstructured":"Gencer B, Mach F, Murphy SA, et al. Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial. JAMA Cardiol. 2020;5(8):952\u20137.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"6261_CR10","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","volume":"74","author":"JW Jukema","year":"2019","unstructured":"Jukema JW, Szarek M, Zijlstra LE, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;74(9):1167\u201376.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"6261_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137(4):338\u201350.","journal-title":"Circulation"},{"issue":"10","key":"6261_CR12","first-page":"Cd011748","volume":"10","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, Carter JL, Pearce LS, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;10(10):Cd011748.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"6261_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.5414\/CP204506","volume":"62","author":"KH Shin","year":"2024","unstructured":"Shin KH, Choi HD. Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2024;62(6):250\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"6261_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14712598.2025.2511063","volume":"25","author":"M Jha","year":"2025","unstructured":"Jha M, Agrawal SP, Maheta D, et al. Efficacy and safety of evolocumab in statin-treated patients with cardiovascular risk factors: a systematic review and meta-analysis. Expert Opin Biol Ther. 2025;25(7):749\u201359.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"6261_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jacc.2023.11.029","volume":"83","author":"DJ McClintick","year":"2024","unstructured":"McClintick DJ, O\u2019Donoghue ML, De Ferrari GM, et al. Long-term efficacy of evolocumab in patients with or without multivessel coronary disease. J Am Coll Cardiol. 2024;83(6):652\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"6261_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1536\/ihj.22-052","volume":"63","author":"Y Hao","year":"2022","unstructured":"Hao Y, Yang YL, Wang YC, Li J. Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome. Int Heart J. 2022;63(4):669\u201377.","journal-title":"Int Heart J"},{"issue":"11","key":"6261_CR17","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.16680\/j.1671-3826.2023.11.07","volume":"51","author":"C Zhang","year":"2023","unstructured":"Zhang C, Xu LS, Zheng HY, Huang DF, Liu YX. Clinical effect of ilulozumab combined with rosuvastatin in the treatment of elderly patients with ultra-high risk atherosclerotic cardiovascular disease. Clin J Med Office. 2023;51(11):1129\u201332.\u00a0[in Chinese] [WANFANG MED ONLINE] .\u00a0https:\/\/doi.org\/10.16680\/j.1671-3826.2023.11.07.","journal-title":"Clin J Med Office."},{"issue":"1","key":"6261_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3969\/j.issn.1009-0126.2025.01.010","volume":"27","author":"C Wang","year":"2025","unstructured":"Wang C, Chen HL, Zhang XP, Sun LW. Effect of combined evolocumab and statins on elderly patients with multi-vessel coronary heart disease. Chin J Geriatr Heart Brain Vessel Dis. 2025;27(1):43\u20137.\u00a0[in Chinese] [WANFANG MED ONLINE].\u00a0https:\/\/doi.org\/10.3969\/j.issn.1009-0126.2025.01.010.","journal-title":"Chin J Geriatr Heart Brain Vessel Dis."},{"issue":"28","key":"6261_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3969\/j.issn.1674-4721.2025.28.16","volume":"32","author":"BZ Chen","year":"2025","unstructured":"Chen BZ, Tao L, Liu F, Xi Q. Influence of Evolocumab on blood lipids and the incidence of cardiovascular events in patients with atherosclerotic cardiovascular diseases. Chin Modern Med. 2025;32(28):74\u20137.\u00a0[in Chinese] [WANFANG MED ONLINE].\u00a0https:\/\/doi.org\/10.3969\/j.issn.1674-4721.2025.28.16.","journal-title":"Chin Modern Med."},{"issue":"10","key":"6261_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3969\/j.issn.0253-9926.2025.10.010","volume":"54","author":"F Yang","year":"2025","unstructured":"Yang F, Yang LW, Zhao YQ. Effect of evolocumab combined with statins on low-density lipoprotein cholesterol level and prognosis in elderly patients with coronary heart disease. Chin J Geriatr Heart Brain Vessel Dis. 2025;54(10):763\u20136.\u00a0[in Chinese] [WANFANG MED ONLINE].\u00a0https:\/\/doi.org\/10.3969\/j.issn.0253-9926.2025.10.010.","journal-title":"Chin J Geriatr Heart Brain Vessel Dis."},{"key":"6261_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"6261_CR22","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"3","key":"6261_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"7414","key":"6261_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"7109","key":"6261_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"2","key":"6261_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455\u201363.","journal-title":"Biometrics"},{"issue":"2","key":"6261_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2514428","volume":"394","author":"EA Bohula","year":"2026","unstructured":"Bohula EA, Marston NA, Bhatia AK, et al. Evolocumab in patients without a previous myocardial infarction or stroke. N Engl J Med. 2026;394(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"20","key":"6261_CR28","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"KC Koskinas","year":"2019","unstructured":"Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"6261_CR29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692\u2013711.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"6261_CR30","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1093\/eurheartj\/ehz430","volume":"43","author":"P Guedeney","year":"2022","unstructured":"Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2022;43(7):e17\u201325.","journal-title":"Eur Heart J"},{"issue":"22","key":"6261_CR31","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373\u201384.","journal-title":"JAMA"},{"issue":"7","key":"6261_CR32","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15(7):1308\u201321.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"18","key":"6261_CR33","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: The PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771\u201381.","journal-title":"JAMA"},{"issue":"2","key":"6261_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jacl.2020.01.015","volume":"14","author":"G Mandraffino","year":"2020","unstructured":"Mandraffino G, Scicali R, Rodr\u00edguez-Carrio J, et al. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: a two-lipid center real-world experience. J Clin Lipidol. 2020;14(2):231\u201340. https:\/\/doi.org\/10.1016\/j.jacl.2020.01.015.","journal-title":"J Clin Lipidol"},{"key":"6261_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.pcad.2025.05.008","volume":"92","author":"G Bosco","year":"2025","unstructured":"Bosco G, Di Giacomo Barbagallo F, Di Marco M, et al. Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience. Prog Cardiovasc Dis. 2025;92:108\u201317. https:\/\/doi.org\/10.1016\/j.pcad.2025.05.008.","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"6261_CR36","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1186\/s12967-025-07432-z","volume":"23","author":"G Bosco","year":"2025","unstructured":"Bosco G, Di Giacomo Barbagallo F, Di Marco M, et al. Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. J Transl Med. 2025;23(1):1371. https:\/\/doi.org\/10.1186\/s12967-025-07432-z.","journal-title":"J Transl Med"},{"issue":"9753","key":"6261_CR37","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"5","key":"6261_CR38","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jacc.2024.11.019","volume":"85","author":"S Al Said","year":"2025","unstructured":"Al Said S, O\u2019Donoghue ML, Ran X, et al. Long-term lipid lowering with evolocumab in older individuals. J Am Coll Cardiol. 2025;85(5):504\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"6261_CR39","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1253\/circj.CJ-20-1051","volume":"85","author":"AC Keech","year":"2021","unstructured":"Keech AC, Oyama K, Sever PS, et al. Efficacy and safety of long-term evolocumab use among Asian subjects - a subgroup analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial. Circ J. 2021;85(11):2063\u201370.","journal-title":"Circ J"},{"issue":"2","key":"6261_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","volume":"138","author":"EA Bohula","year":"2018","unstructured":"Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and cholesterol risk in the FOURIER trial. Circulation. 2018;138(2):131\u201340.","journal-title":"Circulation"},{"issue":"1","key":"6261_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"7","key":"6261_CR42","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(7):633\u201343.","journal-title":"N Engl J Med"},{"issue":"18","key":"6261_CR43","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1016\/j.jacc.2020.03.039","volume":"75","author":"B Gencer","year":"2020","unstructured":"Gencer B, Mach F, Guo J, et al. Cognition after lowering LDL-cholesterol with evolocumab. J Am Coll Cardiol. 2020;75(18):2283\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"6261_CR44","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"15","key":"6261_CR45","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364.","journal-title":"N Engl J Med"},{"issue":"1","key":"6261_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"5","key":"6261_CR47","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/03007995.2022.2049164","volume":"38","author":"H Burnett","year":"2022","unstructured":"Burnett H, Fahrbach K, Cichewicz A, et al. Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis. Curr Med Res Opin. 2022;38(5):777\u201384.","journal-title":"Curr Med Res Opin"},{"key":"6261_CR48","unstructured":"Novartis Pharmaceuticals. Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes. ClinicalTrials.gov. identifier: NCT07102628. Updated [March 9, 2026]. https:\/\/clinicaltrials.gov\/study\/NCT07102628?term=inclisiran&page=3&rank=21. Accessed 19 Mar 2026."}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06261-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06261-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06261-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:15:49Z","timestamp":1791332149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06261-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6261"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06261-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was not required for this study as no human resources were involved.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable for the reasons stated above.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"883"}}